A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 250
Summary
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02975349
- Collaborators
- Merck KGaA, Darmstadt, Germany
- Investigators
- Study Director: Medical Responsible EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany
Get Well Soon